Patents by Inventor Anne Bertolotti
Anne Bertolotti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220313628Abstract: The present invention discloses a method to discover selective inhibitors of phosphatases.Type: ApplicationFiled: May 24, 2022Publication date: October 6, 2022Applicant: United Kingdom Research and InnovationInventors: Anne BERTOLOTTI, Indrajit DAS, Agnieszka KRZYZOSIAK, Adrien ROUSSEAU, Kim SCHNEIDER, Anna Gudny SIGURDARDOTTIR
-
Patent number: 11364211Abstract: The present invention discloses a method to discover selective inhibitors of phosphatases.Type: GrantFiled: April 8, 2016Date of Patent: June 21, 2022Assignee: United Kingdom Research and InnovationInventors: Anne Bertolotti, Indrajit Das, Agnieszka Krzyzosiak, Adrien Rousseau, Kim Schneider, Anna Gudny Sigurdardottir
-
Patent number: 11337941Abstract: The present invention relates to inhibitors of PPP1 R15A and PPP1 R15B and their use in therapy, particularly in the treatment of a disease state alleviated by the inhibition of PPP1 R15A and PPP1 R15B, for example a disorder associated with accumulation of misfolded proteins or proteostatsis disorder. Compounds of the invention include compounds having the formula IA or a pharmaceutically acceptable salt thereof, wherein R1a, R3a, R5a, Xa and Ya are as defined herein.Type: GrantFiled: February 28, 2020Date of Patent: May 24, 2022Assignee: United Kingdom Research and InnovationInventors: Anne Bertolotti, Indrajit Das, Agnieszka Krzyzosiak, Adrien Rousseau, Kim Schneider, Anna Gudny Sigurdardottir
-
Patent number: 11331286Abstract: The present invention relates to inhibitors of PPP1 R15A and PPP1 R15B and their use in therapy, particularly in the treatment of a disease state alleviated by the inhibition of PPP1 R15A and PPP1 R15B, for example a disorder associated with accumulation of misfolded proteins or proteostatsis disorder. Compounds of the invention include compounds having the formula IA or a pharmaceutically acceptable salt thereof, wherein R1a, R3a, R5a, Xa and Ya are as defined herein.Type: GrantFiled: February 28, 2020Date of Patent: May 17, 2022Assignee: United Kingdom Research and InnovationInventors: Anne Bertolotti, Indrajit Das, Agnieszka Krzyzosiak, Adrien Rousseau, Kim Schneider, Anna Gudny Sigurdardottir
-
Patent number: 11154519Abstract: The present invention relates to inhibitors of PPP1 R15A and PPP1 R15B and their use in therapy, particularly in the treatment of a disease state alleviated by the inhibition of PPP1 R15A and PPP1 R15B, for example a disorder associated with accumulation of misfolded proteins or proteostatsis disorder. Compounds of the invention include compounds having the formula IA or a pharmaceutically acceptable salt thereof, wherein R1a, R3a, R5a, Xa and Ya are as defined herein.Type: GrantFiled: April 8, 2016Date of Patent: October 26, 2021Assignee: United Kingdom Research and InnovationInventors: Anne Bertolotti, Indrajit Das, Agnieszka Krzyzosiak, Adrien Rousseau, Kim Schneider, Anna Gudny Sigurdardottir
-
Patent number: 10954198Abstract: The present invention relates to a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, wherein: R1 is alkyl, Cl, F or Br; R2 is H or F; R3 is selected from H and alkyl; R4 is selected from H and C(O)R6; R5 is H; or R4 and R5 are linked to form a heterocyclic group which is optionally substituted with one or more R10 groups; R6 is selected from R7, OR7 and NR8R9; R7, R8 and R9 are each independently selected from alkyl, cycloalkyl, aralkyl, cycloalkenyl, heterocyclyl and aryl, each of which is optionally substituted with one or more R10 groups; each R10 is independently selected from halogen, OH, CN, NO2, COO-alkyl, aralkyl, SO2-alkyl, SO2-aryl, COOH, CO-alkyl, CO-aryl, NH2, NH-alkyl, N(alkyl)2, CF3, alkyl and alkoxy; X and Z are each independently CR11, and Y is selected from CR11 and N; and R11 is H or F; for use in treating a disorder associated with protein misfolding stress and in particular associated with accumulation of misfolded proteins.Type: GrantFiled: November 25, 2019Date of Patent: March 23, 2021Assignees: United Kingdom Research and Innovation, Inflectis BioscienceInventors: Philippe Guedat, Anne Bertolotti
-
Publication number: 20200297668Abstract: The present invention relates to inhibitors of PPP1 R15A and PPP1 R15B and their use in therapy, particularly in the treatment of a disease state alleviated by the inhibition of PPP1 R15A and PPP1 R15B, for example a disorder associated with accumulation of misfolded proteins or proteostatsis disorder. Compounds of the invention include compounds having the formula IA or a pharmaceutically acceptable salt thereof, wherein R1a, R3a, R5a, Xa and Ya are as defined herein.Type: ApplicationFiled: February 28, 2020Publication date: September 24, 2020Applicant: Medical Research CouncilInventors: Anne BERTOLOTTI, Indrajit DAS, Agnieszka KRZYZOSIAK, Adrien ROUSSEAU, Kim SCHNEIDER, Anna Gudny SIGURDARDOTTIR
-
Publication number: 20200197337Abstract: The present invention relates to inhibitors of PPP1 R15A and PPP1 R15B and their use in therapy, particularly in the treatment of a disease state alleviated by the inhibition of PPP1 R15A and PPP1 R15B, for example a disorder associated with accumulation of misfolded proteins or proteostatsis disorder. Compounds of the invention include compounds having the formula IA or a pharmaceutically acceptable salt thereof, wherein R1a, R3a, R5a, Xa and Ya are as defined herein.Type: ApplicationFiled: February 28, 2020Publication date: June 25, 2020Applicant: Medical Research CouncilInventors: Anne BERTOLOTTI, Indrajit DAS, Agnieszka KRZYZOSIAK, Adrien ROUSSEAU, Kim SCHNEIDER, Anna Gudny SIGURDARDOTTIR
-
Publication number: 20200199647Abstract: This invention relates to assays for screening test compounds for their ability to modulate holophosphatase activity.Type: ApplicationFiled: June 21, 2018Publication date: June 25, 2020Inventors: Anne BERTOLOTTI, Marta CARRARA
-
Publication number: 20200095210Abstract: The present invention relates to a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, wherein: R1 is alkyl, Cl, F or Br; R2 is H or F; R3 is selected from H and alkyl; R4 is selected from H and C(O)R6; R5 is H; or R4 and R5 are linked to form a heterocyclic group which is optionally substituted with one or more R10 groups; R6 is selected from R7, OR7 and NR8R9; R7, R8 and R9 are each independently selected from alkyl, cycloalkyl, aralkyl, cycloalkenyl, heterocyclyl and aryl, each of which is optionally substituted with one or more R10 groups; each R10 is independently selected from halogen, OH, CN, NO2, COO-alkyl, aralkyl, SO2-alkyl, SO2-aryl, COOH, CO-alkyl, CO-aryl, NH2, NH-alkyl, N(alkyl)2, CF3, alkyl and alkoxy; X and Z are each independently CR11, and Y is selected from CR11 and N; and R11 is H or F; for use in treating a disorder associated with protein misfolding stress and in particular associated with accumulation of misfolded proteins.Type: ApplicationFiled: November 25, 2019Publication date: March 26, 2020Inventors: Philippe Guedat, Anne Bertolotti
-
Patent number: 10526297Abstract: The present invention relates to a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, wherein R1 is alkyl, Cl, F or Br, R2 is H or F; R3 is selected from H and alkyl; R4 is selected from H and C(O)R6; R5 is H or R4 and R5 are linked to form a heterocyclic group which is optionally substituted with one or more R10 groups R6 is selected from R7, OR7 and NR8R6; R7R8 and R9 are each independently selected from alkyl, cycloalkyl, aralkyl, cycloalkenyl, heterocycyl and aryl, each of which is optionally substituted with one or more R10 groups; each R10 is independently selected from halogen, OH, CN NO1, COO-alkyl, aralkyl, SO2-alkyl, SO2-aryl, COOH, CO-alkyl, CO-aryl, NH2, NH-alkyl, N(alkyl)2, CF3, alkyl and alkoxy, X and Z are each independently CR11 and Y is selected from CR11 and N and R11 is H or F; for use in treating a disorder associated with protein misfolding stress and in particular associated with accumulation of misfolded proteins.Type: GrantFiled: August 31, 2018Date of Patent: January 7, 2020Assignees: InFlectis BioScience, United Kingdom Research and InnovationInventors: Philippe Guedat, Anne Bertolotti
-
Publication number: 20180354914Abstract: The present invention relates to a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, wherein R1 is alkyl, Cl, F or Br, R2 is H or F; R3 is selected from H and alkyl; R4 is selected from H and C(O)R6; R5 is H or R4 and R5 are linked to form a heterocyclic group which is optionally substituted with one or more R10 groups R6 is selected from R7, OR7 and NR8R6; R7R8 and R9 are each independently selected from alkyl, cycloalkyl, aralkyl, cycloalkenyl, heterocycyl and aryl, each of which is optionally substituted with one or more R10 groups; each R10 is independently selected from halogen. OH, CN NO2, COO-alkyl, aralkyl, SO2-alkyl, SO2-aryl, COOH, CO-alkyl, CO-aryl, NH2, NH-alkyl, N(alkyl)2, CF3, alkyl and alkoxy, X and Z are each independently CR11 and Y is selected from CR11 and N and R11 is H or F; for use in treating a disorder associated with protein misfolding stress and in particular associated with accumulation of misfolded proteins.Type: ApplicationFiled: August 31, 2018Publication date: December 13, 2018Inventors: Philippe Guedat, Anne Bertolotti
-
Patent number: 10100020Abstract: The present invention relates to a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, wherein: R1 is alkyl, Cl, F or Br; R2 is H or F; R3 is selected from H and alkyl; R4 is selected from H and C(O)R6; R5 is H; or R4 and R5 are linked to form a heterocyclic group which is optionally substituted with one or more R10 groups; R6 is selected from R7, OR7 and NR8R9; R7, R8 and R9 are each independently selected from alkyl, cycloalkyl, aralkyl, cycloalkenyl, heterocyclyl and aryl, each of which is optionally substituted with one or more R10 groups; each R10 is independently selected from halogen, OH, CN, NO2, COO-alkyl, aralkyl, SO2-alkyl, SO2-aryl, COOH, CO-alkyl, CO-aryl, NH2, NH-alkyl, N(alkyl)2, CF3, alkyl and alkoxy; X and Z are each independently CR11, and Y is selected from CR11 and N; and R11 is H or F; for use in treating a disorder associated with protein misfolding stress and in particular associated with accumulation of misfolded proteins.Type: GrantFiled: March 23, 2017Date of Patent: October 16, 2018Assignees: United Kingdom Research and Innovation, InFlectis BioScienceInventors: Philippe Guedat, Anne Bertolotti
-
Publication number: 20180125801Abstract: The present invention discloses a method to discover selective inhibitors of phosphatases.Type: ApplicationFiled: April 8, 2016Publication date: May 10, 2018Applicant: MEDICAL RESEARCH COUNCILInventors: Anne BERTOLOTTI, Indrajit DAS, Agnieszka KRZYZOSIAK, Adrien ROUSSEAU, Kim SCHNEIDER, Anna Gudny SIGURDARDOTTIR
-
Publication number: 20180111896Abstract: The present invention relates to inhibitors of PPP1 R15A and PPP1 R15B and their use in therapy, particularly in the treatment of a disease state alleviated by the inhibition of PPP1 R15A and PPP1 R15B, for example a disorder associated with accumulation of misfolded proteins or proteostatsis disorder. Compounds of the invention include compounds having the formula IA or a pharmaceutically acceptable salt thereof, wherein R1a, R3a, R5a, Xa and Ya are as defined herein.Type: ApplicationFiled: April 8, 2016Publication date: April 26, 2018Applicant: MEDICAL RESEARCH COUNCILInventors: Anne BERTOLOTTI, Indrajit DAS, Agnieszka KRZYZOSIAK, Adrien ROUSSEAU, Kim SCHNEDIDER, Anna Gudny SICURDARDOTTIR
-
Publication number: 20170247344Abstract: The present invention relates to a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, wherein: R1 is alkyl, Cl, F or Br; R2 is H or F; R3 is selected from H and alkyl; R4 is selected from H and C(O)R6; R5 is H; or R4 and R5 are linked to form a heterocyclic group which is optionally substituted with one or more R10 groups; R6 is selected from R7, OR7 and NR8R9; R7, R8 and R9 are each independently selected from alkyl, cycloalkyl, aralkyl, cycloalkenyl, heterocyclyl and aryl, each of which is optionally substituted with one or more R10 groups; each R10 is independently selected from halogen, OH, CN, NO2, COO-alkyl, aralkyl, SO2-alkyl, SO2-aryl, COOH, CO-alkyl, CO-aryl, NH2, NH-alkyl, N(alkyl)2, CF3, alkyl and alkoxy; X and Z are each independently CR11, and Y is selected from CR11 and N; and R11 is H or F; for use in treating a disorder associated with protein misfolding stress and in particular associated with accumulation of misfolded proteins.Type: ApplicationFiled: March 23, 2017Publication date: August 31, 2017Inventors: Philippe Guedat, Anne Bertolotti
-
Patent number: 9682943Abstract: The present invention relates to a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, wherein: R1 is alkyl, Cl, F or Br; R2 is H or F; R3 is selected from H and alkyl; R4 is selected from H and C(O)R6; R5 is H; or R4 and R5 are linked to form a heterocyclic group which is optionally substituted with one or more R10 groups; R6 is selected from R7, OR7 and NR8R9; R7, R8 and R9 are each independently selected from alkyl, cycloalkyl, aralkyl, cycloalkenyl, heterocyclyl and aryl, each of which is optionally substituted with one or more R10 groups; each R10 is independently selected from halogen, OH, CN, NO2, COO-alkyl, aralkyl, SO2-alkyl, SO2-aryl, COOH, CO-alkyl, CO-aryl, NH2, NH-alkyl, N(alkyl)2, CF3, alkyl and alkoxy; X and Z are each independently CR11, and Y is selected from CR11 and N; and R11 is H or F; for use in treating a disorder associated with protein misfolding stress and in particular associated with accumulation of misfolded proteins.Type: GrantFiled: January 10, 2014Date of Patent: June 20, 2017Assignees: MEDICAL RESEARCH COUNCIL, INFLECTIS BIOSCIENCEInventors: Philippe Guedat, Anne Bertolotti
-
Publication number: 20160046589Abstract: The present invention relates to a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, wherein: R1 is alkyl, Cl, F or Br; R2 is H or F; R3 is selected from H and alkyl; R4 is selected from H and C(O)R6; R5 is H; or R4 and R5 are linked to form a heterocyclic group which is optionally substituted with one or more R10 groups; R6 is selected from R7, OR7 and NR8R9; R7, R8 and R9 are each independently selected from alkyl, cycloalkyl, aralkyl, cycloalkenyl, heterocyclyl and aryl, each of which is optionally substituted with one or more R10 groups; each R10 is independently selected from halogen, OH, CN, NO2, COO-alkyl, aralkyl, SO2-alkyl, SO2-aryl, COOH, CO-alkyl, CO-aryl, NH2, NH-alkyl, N(alkyl)2, CF3, alkyl and alkoxy; X and Z are each independently CR11, and Y is selected from CR11 and N; and R11 is H or F; for use in treating a disorder associated with protein misfolding stress and in particular associated with accumulation of misfolded proteins.Type: ApplicationFiled: January 10, 2014Publication date: February 18, 2016Inventors: Philippe Guedat, Anne Bertolotti
-
Patent number: 7932422Abstract: The invention relates to chlorine Guanabenz derivatives for treating Huntington's disease and other polyglutamine expansion associated diseases. More specifically, it relates to the use of the molecule of formula (I) wherein R?H or Cl and the phenyl group is at least substituted twice, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating polyglutamine expansion associated diseases.Type: GrantFiled: October 3, 2007Date of Patent: April 26, 2011Inventors: Anne Bertolotti, Marc Blondel
-
Publication number: 20110092483Abstract: A kit and a method for identifying compounds having anti-prion activity are provided. The kit comprises a yeast of phenotype [PSI+]; an antibiogram; and a prion curing agent in a sub-effective dose, wherein the yeast has the adel-14 allele of the ADE1 gene and an inactivated ERG6 gene. Compounds and pharmaceutical compositions having anti-prion activity are also provided, which are useful for treating various neurodegenerative diseases, including polyglutamines expansion associated diseases; Huntington's disease; Kennedy disease; amyotrophic lateral sclerosis; cerebellous autosomic ataxies; dentalorubral-pallidoluysian atrophy; and spino-bulbar amyotrophy.Type: ApplicationFiled: August 17, 2010Publication date: April 21, 2011Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE VICTOR SEGALEN BORDEAUX 2, UNIVERSITE DE POITIERSInventors: MARC BLONDEL, CHRISTOPHE CULLIN, JEAN MICHEL VIERFOND, ANNE BERTOLOTTI, STÉPHANE BACH, NICOLAS TALAREK, YVETTE METTEY